Genolier Swiss Medical Network (GSMN): Results affected by acquisitions and developments

Genolier Swiss Medical Network (GSMN) / Final Results/Final Results

29.04.2010 07:31

Dissemination of a Adhoc News, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

9.0% increase in turnover to CHF 139.3 million

Genolier Swiss Medical Network (GSMN.SW) today published its Annual Report
for 2009. With the sale of Agefi and the acquisition of the Bethanien
Clinic in Zurich, 2009 was a significant year for the Group, giving it a
real national dimension. Turnover increased by 9.0% to CHF 139.3 million
(CHF 127.8 m), and most of the units are showing growth and posting
improved results. EBITDA according to IFRS, which was adversely affected by
the costs of acquisition, development and restructuring, fell to CHF 8.9
million (CHF 10.5 m). Including the extraordinary profit associated with
the sale of Agefi, the Group achieved net income of CHF 1.9 million (CHF
0.2 m). GSMN will present its first financial statements as per SWISS GAAP
FER in the first half of 2010. In 2009, according to Swiss GAAP, EBITDA
would have amounted to CHF 10.4 million and net income to CHF 3.7 million.

GSMN's turnover in 2009 was CHF 139.3 million, an increase of 9.0% over
2008. Since Centre médico-chirurgical des Eaux-Vives has been consolidated
since March 2009, the increase would have been 3.6% on a like-for-like
basis. EBITDA according to IFRS, with a drop of 15.4% to CHF 8.9 million,
has been adversely affected by the costs of acquisition and development.
Including the transfer of 51% of AGEFI, the Group's net income rose to CHF
1.9 million. Operating cash flow fell slightly to CHF 9 million. Staff
costs associated with overheads accounted for just 2.9% of turnover (3.8%
in 2008), and this percentage will fall even further with the consolidation
of Bethanien in 2010. GSMN expects to achieve a turnover of almost CHF 200
million in 2010.

At the individual clinic level, Clinique de Genolier, which continued to
develop in 2009, achieved a turnover of CHF 74.1 million (CHF 70.0m). The
opening of the secure healthcare residence 'Les Hauts de Genolier' has
increased the capacity of the site. On the other hand, costs associated
with this opening had an adverse impact of almost CHF 1 million on
Genolier's results in 2009. The effect is expected to be neutral in 2010
and positive from 2011. With a turnover of CHF 16.9 million, Clinique de
Montchoisi has proved to be the most productive establishment per bed and
m2. By the end of 2010, the Lausanne-based clinic will benefit from a new
370 m2 Radiology Centre, an underground car park with 45 spaces and a
restaurant, thereby allowing its continued growth. These important projects
have negatively impacted EBITDA in 2009 by some CHF 0.5 million, but they
offer the prospect of an increase of almost 35% in turnover.

Clinique Générale in Fribourg has now reached cruising speed, with a
turnover of CHF 27.5 million and an EBITDA of CHF 2.2 million. For Clinique
Valmont, 2009 has been a key year, with the relinquishment of cardiac
rehabilitation and a refocusing on private and semi-private clients. These
restructuring measures will eventually make the clinic more profitable.
Centre Médico-Chirurgical des Eaux-Vives, acquired in March 2009, has
contributed some CHF 6.9 million to Group turnover and CHF 0.8 million to
EBITDA. Its radio-oncology centre currently treats almost 30 patients a day
and offers exceptional technical facilities to the physicians and patients
of Geneva.

From an organic standpoint, the Group has the capacity to enjoy significant
growth and is currently focusing on the recruitment of new panel doctors
and new agents in other countries. Similarly, intensive efforts focusing on
the patient mix should enable the Group to achieve qualitative growth in
both turnover and EBITDA. On the other hand, the financial and economic
crisis has significantly reduced the multiples applied to transactions in
this sector. Together with the uncertain legislative environment, this
factor obviously opens up interesting acquisition prospects for GSMN.

The Annual Report for 2009 is available on the website
(http://ir.gsmn.ch/cgi-bin/show.ssp?companyName=genolierswiss&language=Eng
lish&id=1).


Genolier Swiss Medical Network AG (GSMN) is a major private hospital
network in Switzerland. Its growth strategy is focused on building a
national network by acquiring clinics and integrating their operations.
GSMN's main goal is to provide premium hospital care to Swiss and foreign
patients. GSMN stands out through its high-quality services, brand value,
congenial working environment and an experienced and entrepreneurial
management team. GSMN currently manages 6 private facilities (Clinique de
Genolier, Privatklinik Bethanien, Clinique de Montchoisi, Clinique Valmont,
Clinique Générale and Centre medico-chirurgical des Eaux-Vives), with over
550 admitting physicians and 1'027 employees. The Group is listed on the
Main Segment of the SIX Swiss Exchange (GSMN.SW).


---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

GSMN SA Press Service   
Séverine Van der Schueren
General Secretary
Tel. +41 22 366 99 87
svanderschueren@gsmn.ch


Service de Presse GSMN SA  
Séverine Van der Schueren 
Secrétaire Générale
Tél. 022 366 99 87
svanderschueren@gsmn.ch





29.04.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
Back